Catheter Precision to Attend the Annual European Heart Rhythm Association Conference
Rhea-AI Summary
Catheter Precision (NYSE American: VTAK) will attend the annual European Heart Rhythm Association (EHRA) conference in Paris from April 12–14, 2026. The company said it will use the event to share new data, engage key opinion leaders and educate physicians and distributors about LockeT after CE Mark receipt.
This appearance is the company's first large European conference since LockeT received CE Mark clearance and aims to support expanded product use and commercial momentum.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – VTAK
On the day this news was published, VTAK declined 1.73%, reflecting a mild negative market reaction. Argus tracked a peak move of +38.8% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $60K from the company's valuation, bringing the market cap to $3.42M at that time. Trading volume was exceptionally heavy at 7.6x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Before this news, VTAK showed a -7.65% move with very light volume while key medical device peers like NUWE, BBLG, BJDX, and VERO showed positive daily changes, and NAOV and BMRA were down. The mixed and often opposite peer moves indicate this looks stock-specific rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 06 | LockeT clinical data | Positive | +2.1% | Peer-reviewed LockeT study in 139 patients showing strong procedural outcomes. |
| Apr 02 | Asset sale process | Positive | -1.1% | Engaged advisor to market electrophysiology business and refocus on Flyte platform. |
| Mar 31 | 2025 results & strategy | Negative | -3.8% | Reported revenue growth but significant net loss while outlining dual-platform strategy. |
| Mar 25 | Aviation expansion | Positive | -4.2% | Announced expansion of Vision Jet Hops regional platform and fleet growth plans. |
| Mar 16 | Flyte Hops launch | Positive | +4.4% | Launched Flyte Hops Florida with strong initial bookings and fleet expansion goals. |
Recent news has been generally positive or strategic, but price reactions have been mixed, with three aligned moves and two cases where positive developments saw negative follow-through.
Over the past month, Catheter Precision reported multiple developments across medical devices and aviation. On Mar 16, Flyte Hops Florida launched with over $160,000 in bookings and a plan for at least five Cirrus Vision Jets by Memorial Day 2026, followed by Vision Jet platform expansion news on Mar 25. Full-year 2025 results released on Mar 31 highlighted $819 thousand revenue, 92.3% gross margin, and a $17.2 million net loss. In early April, the company engaged a strategic advisor to market its electrophysiology assets and announced positive LockeT data in 139 patients. Today’s EHRA conference attendance continues the LockeT-focused visibility push.
Market Pulse Summary
This announcement highlights Catheter Precision’s participation at the EHRA conference from April 12–14, 2026, emphasizing LockeT exposure after receiving the CE Mark and following new clinical data in 139 patients. It continues a series of updates spanning Flyte aviation growth and 2025 financials, which showed revenue of $819 thousand, 92.3% gross margin, and a significant net loss. Investors may monitor how conference engagement translates into LockeT adoption, potential asset monetization, and progress against liquidity and capital‑raising risks disclosed in recent SEC filings.
Key Terms
european heart rhythm association medical
ehra medical
european society of cardiology medical
ce mark regulatory
electrophysiology medical
AI-generated analysis. Not financial advice.
FORT MILL, S.C., April 08, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company”) today announced that it will be attending the annual European Heart Rhythm Association (EHRA) conference in Paris, France from April 12-14, 2026.
EHRA is one of several conferences supported by the European Society of Cardiology whose mission is to reduce the number of people with cardiovascular diseases by connecting cardiovascular health professionals around the world to disseminate the latest knowledge, innovations and guidelines. As a community, they work together to empower healthcare providers to transform cardiovascular care from a privilege to a universal right.
David Jenkins, CEO of Catheter Precision, says, “Conferences continue to be a top priority for Catheter Precision. It is at these events that we can share our newest data and meet with key opinion leaders in the electrophysiology field. EHRA 2026 is exciting as this is the first large European conference we are attending since receipt of the CE Mark for LockeT. This is the perfect opportunity to educate new physicians and distributors about LockeT and continue the forward momentum and expanded product use.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About VIVO™
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “anticipate,” “potential,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, expectations regarding potential strategic transactions, valuation outcomes, market opportunities, and the Company’s growth strategy. These statements involve risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the Company’s filings with the SEC, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
